Official data from INPI

122023019225

Prazo de SigiloUtility ModelPCT · US2019052608

Talk to an expert

Application data

Number

122023019225

Type

Utility Model

Filing

09/24/2019

Publication

PCT

US2019052608

View on INPI

Progress at the INPI

Filing09/24/19
Publication
Examination
Allowance
Grant
In force

The application was filed at the INPI on 09/24/2019. It awaits formal examination and publication in the RPI gazette.

Latest action published by the INPI: 12/26/2023. We update with every new RPI gazette, published weekly.

Applicants and inventors

Applicants

IMPACT BIOMEDICINES, INC.

See this company's full portfolio

Inventors

No inventors listed.

Technical data

IPC Classification

No IPC classification.

Prosecution history

Publications in the Brazilian Industrial Property Gazette (RPI).

Notificação de pedido dividido

#2.4

12/26/2023

RPI 2764

Requerimento de pedido de patente

#2.10

Número de Protocolo '870230083516' em 20/09/2023 18:07 (WB)

10/03/2023

RPI 2752

From the same holder

USO DE UM INIBIDOR DE BET SOZINHO OU EM COMBINAÇÃO COM FEDRATINIBE OU RUXOLITINIBE PARA TRATAMENTO DE UMA MALIGNIDADE HEMATOLÓGICA, TAL COMO MIELOFIBROSE DOSAGEM DE FEDRATINIBE FORMAS CRISTALINAS DE UM INIBIDOR DE JAK2 COMPOSTOS DE FEDRATINIBE, SEUS USOS E AGENTE TERAPÊUTICO COMPREENDENDO OS MESMOS USOS DE UM COMPOSTO OU SAL OU HIDRATO DO MESMO PARA TRATAR DISTÚRBIOS MIELOPROLIFERATIVOS 122021012473 122021012465

Patent monitoring

Track this patent in real time.

Receive alerts on INPI events, decisions, and expiry dates for your portfolio.